Update on Bladder Cancer Risk Factors
A recent review provided an update on traditional and novel risk factors for bladder cancer that may help guide prevention efforts.
Bladder Cancer
BLADDER CANCER ADVISOR
FEATURED CONTENT
-
-
The Cost of Bladder Cancer Care Is Rising. Could Value-Based Care Models Help?
The rising cost of care is having a negative impact on patients with bladder cancer, but a value-based approach to care might provide some relief. -
MIBC Tumor Subtypes May Guide Neoadjuvant Chemotherapy Use
Neoadjuvant chemotherapy response rates differed among patients with genomically unstable bladder tumors, urothelial-like bladder tumors, and basal/squamous subtypes. -
Algorithm Proposed to Expand Cisplatin Eligibility for MIBC
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer. -
FDA Label Restriction Triggers Increased Uptake of PD-L1 Assays in Urothelial Carcinoma
FDA label changes for certain immunotherapies may have prompted a marked increase in the use of PD-L1 assays.
BLADDER CANCER NEWS
Erdafitinib Bests Chemotherapy in FGFR-Altered Metastatic Urothelial Carcinoma
Trimodality Therapy and Radical Cystectomy Produce Similar Outcomes in MIBC
Early Death May Be Common in Cancer Patients Taking Immune Checkpoint Inhibitors
5-ARIs May Protect Against Bladder Cancer Progression
High TMB Associated With Better Outcomes of ICI Therapy in Advanced Cancers
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Bladder Cancer
Loading... 
Loading...